Abstract Immune checkpoint blockade (ICB) targeting programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte protein 4 (CTLA-4) can induce remarkable, yet unpredictable, responses across a variety of cancers. Studies suggest that there is a relationship between a cancer patient’s gut microbiota composition and clinical response to ICB; however, defining microbiome-based biomarkers that generalize across cohorts has been challenging.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Ben Markman
Is there a role for combined anti-PD‐1/CTLA‐4 checkpoint blockade in the management of advanced biliary tract cancers?
Jonathan Cebon MD, PhD Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia Search for more papers by this author
Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1/CTLA-4 combination immunotherapy
; ). More recently, Keynote 158, a clinical trial of pembrolizumab (anti-PD-1) monotherapy demonstrated an increased response rate in patients with TMB Tumor mutational burden (TMB) was initially shown to be of predictive value in non-small-cell lung cancer patients treated with anti-programmed cell death protein 1(PD-1)/programmed death-ligand 1 (PD-L1) agents ( high tumors (≥10 mutations per megabase (MB) genome) in a pan-tumor cohort ( Marabelle et al., 2020 Marabelle A. Fakih M. Lopez J. Shah M.
Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial | JAMA Oncology | JAMA Network
Original Investigation July 30, 2020 JAMA Oncol. 2020;6(9):1405-1409. doi:10.1001/jamaoncol.2020.2814 Key Points Question Is combination immunotherapy with nivolumab and ipilimumab associated with positive outcomes in patients with advanced biliary tract cancers?
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial
Summary Background Rationale exists for combined treatment with immune checkpoint inhibitors and poly (ADP-ribose) polymerase (PARP) inhibitors in a variety of solid tumours. This study aimed to investigate the safety and antitumour effects of pamiparib, an oral PARP 1/2 inhibitor, combined with tislelizumab, a humanised anti-PD-1 monoclonal antibody, in patients with advanced solid tumours and to determine the optimum doses for further evaluation.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Ben
Contact Ben, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack